Literature DB >> 22178756

The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast epithelium.

Justin M Balko1, Todd W Miller, Meghan M Morrison, Katherine Hutchinson, Christian Young, Cammie Rinehart, Violeta Sánchez, David Jee, Kornelia Polyak, Aleix Prat, Charles M Perou, Carlos L Arteaga, Rebecca S Cook.   

Abstract

ErbB3 harbors weak kinase activity, but strongly activates downstream phosphatidylinositol 3-kinase/Akt signaling through heterodimerization with and activation by other ErbB receptor tyrosine kinases. We report here that ErbB3 loss in the luminal mammary epithelium of mice impaired Akt and MAPK signaling and reduced luminal cell proliferation and survival. ERBB3 mRNA expression levels were highest in luminal mammary populations and lowest in basal cell/stem cell populations. ErbB3 loss in mammary epithelial cells shifted gene expression patterns toward a mammary basal cell/stem cell signature. ErbB3 depletion-induced gene expression changes were rescued upon activation of Akt and MAPK signaling. Interestingly, proliferation and expansion of the mammary basal epithelium (BE) occurred upon ErbB3 targeting in the luminal epithelium, but not upon its targeting in the BE. Multiple cytokines, including interleukin 6, were induced upon ErbB3 depletion in luminal epithelium cells, which increased growth of BE cells. Taken together, these results suggest that ErbB3 regulates the balance of differentiated breast epithelial cell types by regulating their growth and survival through autocrine- and paracrine-signaling mechanisms.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22178756      PMCID: PMC3252958          DOI: 10.1073/pnas.1115802109

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  34 in total

1.  Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions.

Authors:  R Pinkas-Kramarski; L Soussan; H Waterman; G Levkowitz; I Alroy; L Klapper; S Lavi; R Seger; B J Ratzkin; M Sela; Y Yarden
Journal:  EMBO J       Date:  1996-05-15       Impact factor: 11.598

2.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.

Authors:  T Sørlie; C M Perou; R Tibshirani; T Aas; S Geisler; H Johnsen; T Hastie; M B Eisen; M van de Rijn; S S Jeffrey; T Thorsen; H Quist; J C Matese; P O Brown; D Botstein; P E Lønning; A L Børresen-Dale
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-11       Impact factor: 11.205

3.  Molecular portraits of human breast tumours.

Authors:  C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

4.  Cre-mediated gene deletion in the mammary gland.

Authors:  K U Wagner; R J Wall; L St-Onge; P Gruss; A Wynshaw-Boris; L Garrett; M Li; P A Furth; L Hennighausen
Journal:  Nucleic Acids Res       Date:  1997-11-01       Impact factor: 16.971

Review 5.  The ErbB receptors and their role in cancer progression.

Authors:  Thomas Holbro; Gianluca Civenni; Nancy E Hynes
Journal:  Exp Cell Res       Date:  2003-03-10       Impact factor: 3.905

6.  The erbB3 gene product is a receptor for heregulin.

Authors:  K L Carraway; M X Sliwkowski; R Akita; J V Platko; P M Guy; A Nuijens; A J Diamonti; R L Vandlen; L C Cantley; R A Cerione
Journal:  J Biol Chem       Date:  1994-05-13       Impact factor: 5.157

7.  The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation.

Authors:  Thomas Holbro; Roger R Beerli; Francisca Maurer; Magdalena Koziczak; Carlos F Barbas; Nancy E Hynes
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-09       Impact factor: 11.205

8.  Impaired differentiation and lactational failure of Erbb4-deficient mammary glands identify ERBB4 as an obligate mediator of STAT5.

Authors:  Weiwen Long; Kay-Uwe Wagner; K C Kent Lloyd; Nadine Binart; Jonathan M Shillingford; Lothar Hennighausen; Frank E Jones
Journal:  Development       Date:  2003-09-03       Impact factor: 6.868

9.  ErbB3 is required for normal cerebellar and cardiac development: a comparison with ErbB2-and heregulin-deficient mice.

Authors:  S L Erickson; K S O'Shea; N Ghaboosi; L Loverro; G Frantz; M Bauer; L H Lu; M W Moore
Journal:  Development       Date:  1997-12       Impact factor: 6.868

10.  Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma.

Authors:  D M Abd El-Rehim; S E Pinder; C E Paish; J A Bell; R S Rampaul; R W Blamey; J F R Robertson; R I Nicholson; I O Ellis
Journal:  Br J Cancer       Date:  2004-10-18       Impact factor: 7.640

View more
  40 in total

1.  ErbB3 downregulation enhances luminal breast tumor response to antiestrogens.

Authors:  Meghan M Morrison; Katherine Hutchinson; Michelle M Williams; Jamie C Stanford; Justin M Balko; Christian Young; Maria G Kuba; Violeta Sánchez; Andrew J Williams; Donna J Hicks; Carlos L Arteaga; Aleix Prat; Charles M Perou; H Shelton Earp; Suleiman Massarweh; Rebecca S Cook
Journal:  J Clin Invest       Date:  2013-09-03       Impact factor: 14.808

2.  Dietary suppression of the mammary CD29(hi)CD24(+) epithelial subpopulation and its cytokine/chemokine transcriptional signatures modifies mammary tumor risk in MMTV-Wnt1 transgenic mice.

Authors:  Omar M Rahal; Heather L Machado; Maria Theresa E Montales; John Mark P Pabona; Melissa E Heard; Shanmugam Nagarajan; Rosalia C M Simmen
Journal:  Stem Cell Res       Date:  2013-08-15       Impact factor: 2.020

3.  Developmental Insights into Breast Cancer Intratumoral Heterogeneity.

Authors:  Mei Zhang; Jeffrey M Rosen
Journal:  Trends Cancer       Date:  2015-12-01

Review 4.  Alteration of WWOX in human cancer: a clinical view.

Authors:  Izabela Baryła; Ewa Styczeń-Binkowska; Andrzej K Bednarek
Journal:  Exp Biol Med (Maywood)       Date:  2015-02-13

5.  Gonadotropin-Dependent Neuregulin-1 Signaling Regulates Female Rat Ovarian Granulosa Cell Survival.

Authors:  Indrajit Chowdhury; Alicia Branch; Sharifeh Mehrabi; Byron D Ford; Winston E Thompson
Journal:  Endocrinology       Date:  2017-10-01       Impact factor: 4.736

6.  Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2-Amplified Breast Cancers.

Authors:  Meghan Morrison Joly; Donna J Hicks; Bayley Jones; Violeta Sanchez; Monica Valeria Estrada; Christian Young; Michelle Williams; Brent N Rexer; Dos D Sarbassov; William J Muller; Dana Brantley-Sieders; Rebecca S Cook
Journal:  Cancer Res       Date:  2016-04-25       Impact factor: 12.701

7.  Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors.

Authors:  Anindita Chakrabarty; Neil E Bhola; Cammie Sutton; Ritwik Ghosh; María Gabriela Kuba; Bhuvanesh Dave; Jenny C Chang; Carlos L Arteaga
Journal:  Cancer Res       Date:  2012-11-29       Impact factor: 12.701

8.  MerTK inhibition in tumor leukocytes decreases tumor growth and metastasis.

Authors:  Rebecca S Cook; Kristen M Jacobsen; Anne M Wofford; Deborah DeRyckere; Jamie Stanford; Anne L Prieto; Elizabeth Redente; Melissa Sandahl; Debra M Hunter; Karen E Strunk; Douglas K Graham; H Shelton Earp
Journal:  J Clin Invest       Date:  2013-07-08       Impact factor: 14.808

9.  Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling.

Authors:  Christian D Young; Adam D Pfefferle; Philip Owens; María G Kuba; Brent N Rexer; Justin M Balko; Violeta Sánchez; Hailing Cheng; Charles M Perou; Jean J Zhao; Rebecca S Cook; Carlos L Arteaga
Journal:  Cancer Res       Date:  2013-04-30       Impact factor: 12.701

Review 10.  Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Med Sci (Basel)       Date:  2020-03-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.